DarioHealth (NASDAQ:DRIO) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of DarioHealth (NASDAQ:DRIO) from a sell rating to a hold rating in a report released on Saturday.

A number of other research firms have also recently issued reports on DRIO. Cowen reissued a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Stifel Nicolaus set a $16.00 price objective on DarioHealth in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $32.00.

DarioHealth Stock Up 1.8%

DarioHealth stock opened at $12.44 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.55 and a quick ratio of 4.02. The firm has a fifty day moving average price of $11.95 and a two-hundred day moving average price of $12.07. The firm has a market cap of $84.09 million, a price-to-earnings ratio of -1.11 and a beta of 1.05. DarioHealth has a fifty-two week low of $5.93 and a fifty-two week high of $17.74.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd increased its position in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the quarter. XTX Topco Ltd owned about 0.14% of DarioHealth worth $42,000 as of its most recent SEC filing. 33.39% of the stock is owned by institutional investors and hedge funds.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.